Elena B Volokhina
Overview
Explore the profile of Elena B Volokhina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
616
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bouwmeester R, Duineveld C, Wijnsma K, Bemelman F, van der Heijden J, van Wijk J, et al.
Kidney Int Rep
. 2023 Jan;
8(1):91-102.
PMID: 36644349
Introduction: The introduction of eculizumab has improved the outcome in patients with atypical hemolytic uremic syndrome (aHUS). The optimal treatment strategy is debated. Here, we report the results of the...
2.
Michels M, Volokhina E, van de Kar N, van den Heuvel L
Front Immunol
. 2022 Dec;
13:1036136.
PMID: 36451820
Nephritic factors (NeFs) are autoantibodies promoting the activity of the central enzymes of the complement cascade, an important first line of defense of our innate immune system. NeFs stabilize the...
3.
Ter Avest M, Bouwmeester R, Duineveld C, Wijnsma K, Volokhina E, van den Heuvel L, et al.
Nephrol Dial Transplant
. 2022 Mar;
38(2):362-371.
PMID: 35238929
Background: Eculizumab is a lifesaving yet expensive drug for atypical haemolytic uraemic syndrome (aHUS). Current guidelines advise a fixed-dosing schedule, which can be suboptimal and inflexible in the individual patient....
4.
de Jong S, de Breuk A, Bakker B, Katti S, Hoyng C, Nilsson S, et al.
Front Immunol
. 2022 Jan;
12:789897.
PMID: 35069568
Complement factor I (FI) is a central inhibitor of the complement system, and impaired FI function increases complement activation, contributing to diseases such as age-related macular degeneration (AMD) and atypical...
5.
Michels M, Maas R, van der Velden T, van de Kar N, van den Heuvel L, Volokhina E
J Immunol
. 2021 Oct;
207(10):2465-2472.
PMID: 34635587
The complement system is an important part of innate immunity. Complement activation leads to formation of convertase enzymes, switch of their specificity from C3 to C5 cleavage, and generation of...
6.
de Jong S, de Breuk A, Volokhina E, Bakker B, Garanto A, Fauser S, et al.
Hum Mol Genet
. 2021 Sep;
31(3):455-470.
PMID: 34508573
Age-related macular degeneration (AMD) is a major cause of vision loss among the elderly in the Western world. Genetic variants in the complement factor H (CFH) gene are associated with...
7.
Michels M, Wijnsma K, Kurvers R, Westra D, Schreuder M, van Wijk J, et al.
Pediatr Nephrol
. 2021 Sep;
37(3):601-612.
PMID: 34476601
Background: C3 glomerulopathy (C3G) is a rare kidney disorder characterized by predominant glomerular depositions of complement C3. C3G can be subdivided into dense deposit disease (DDD) and C3 glomerulonephritis (C3GN)....
8.
Michels M, van de Kar N, van Kraaij S, Sarlea S, Gracchi V, Engels F, et al.
Front Immunol
. 2021 Aug;
12:715704.
PMID: 34456924
The rare and heterogeneous kidney disorder C3 glomerulopathy (C3G) is characterized by dysregulation of the alternative pathway (AP) of the complement system. C3G is often associated with autoantibodies stabilizing the...
9.
Michels M, van de Kar N, Volokhina E, van den Heuvel B
Methods Mol Biol
. 2021 Apr;
2227:83-96.
PMID: 33847933
The complement system is a key part of innate immunity. However, if the system becomes dysregulated, damage to healthy host cells can occur, especially to the glomerular cells of the...
10.
de Jong S, Gagliardi G, Garanto A, de Breuk A, Lechanteur Y, Katti S, et al.
Prog Retin Eye Res
. 2021 Feb;
84:100952.
PMID: 33610747
Age-related macular degeneration (AMD) is the main cause of vision loss among the elderly in the Western world. While AMD is a multifactorial disease, the complement system was identified as...